AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Wu, Qin Jie ^a   Gong, Chang Yang ^a   Luo, Shun Tao ^a   Zhang, Dong Mei ^a   Zhang, Shuang ^a   Shi, Hua Shan ^a   Lu, Lian ^a   Yan, Heng Xiu ^a   He, Sha Sha ^a   Li, Dan Dan ^a   Yang, Li ^a   Zhao, Xia ^b   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

AAV; Antiangiogesis; Gene therapy; PEDF; Tumor

Indexed keywords

PARVOVIRUS VECTOR; PIGMENT EPITHELIUM DERIVED FACTOR; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES FLUID; BEHAVIOR CHANGE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CARDIOTOXICITY; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEEDING DISORDER; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LUNG TOXICITY; METASTASIS INHIBITION; MICROVASCULATURE; MOUSE; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; SPLEEN DISEASE; TRANSMISSION ELECTRON MICROSCOPY; UMBILICAL VEIN ENDOTHELIAL CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; WEIGHT REDUCTION; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA; DRUG EFFECT; GENE THERAPY; GENE VECTOR; GENETICS; METASTASIS; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PERITONEUM TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EYE PROTEINS; GENE THERAPY; GENETIC VECTORS; MICE; MICE, INBRED BALB C; MICROVESSELS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; PERITONEAL NEOPLASMS; SERPINS;

EID: 84859053294     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-129     Document Type: Article

References (45)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
2. Ozols RF, Bookman MA, Young RC. Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med 2006, 354(15):1641-1643.
3. Armstrong D, Bundy B, Wenzel L, Huang H, Baergen R, Lele S, Copeland L, Walker J, Burger R. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. N Engl J Med 2006, 354:34-43. 10.1056/NEJMoa052985, 16394300.
4. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going?. J Natl Cancer Inst 1997, 89(1):21. 10.1093/jnci/89.1.21, 8978404.
5. Hansen S, Grabau DA, Sørensen FB, Bak M, Vach W, Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Canc Res 2000, 6(1):139.
6. Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J, Qian C. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003, 8(1):72-79. 10.1016/S1525-0016(03)00128-X, 12842430.
7. Nie B, Shen Z, Wen JB, Wong OGW, Hsueh WD, Huo LF, Kung HF, Jiang B, Lin M. AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer. Mol Cancer Ther 2008, 7(9):2855. 10.1158/1535-7163.MCT-08-0366, 18790766.
8. Cai J, Parr C, Watkins G, Jiang WG, Boulton M. Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res 2006, 12(11):3510. 10.1158/1078-0432.CCR-06-0094, 16740777.
9. Mahtabifard A, Merritt RE, Yamada RE, Crystal RG, Korst RJ. In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies* 1. J Thorac Cardiovasc Surg 2003, 126(1):28-38. 10.1016/S0022-5223(02)73616-7, 12878936.
10. Becerra SP, Sagasti A, Spinella P, Notario V. Pigment epithelium-derived factor behaves like a noninhibitory serpin. J Biol Chem 1995, 270(43):25992. 10.1074/jbc.270.43.25992, 7592790.
11. Ek ETH, Dass CR, Choong PFM. Pigment epithelium-derived factor: a multimodal tumor inhibitor. Mol Cancer Ther 2006, 5(7):1641. 10.1158/1535-7163.MCT-06-0107, 16891449.
12. Dawson D, Volpert O, Gillis P, Crawford S, Xu HJ, Benedict W, Bouck N. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285(5425):245. 10.1126/science.285.5425.245, 10398599.
13. Houenou LJ, D'Costa AP, Li L, Turgeon VL, Enyadike C, Alberdi E, Becerra SP. Pigment epithelium-derived factor promotes the survival and differentiation of developing spinal motor neurons. J Comp Neurol 1999, 412(3):506-514. 10.1002/(SICI)1096-9861(19990927)412:3<506::AID-CNE9>3.0.CO;2-E, 10441236.
14. Hase R, Miyamoto M, Uehara H, Kadoya M, Ebihara Y, Murakami Y, Takahashi R, Mega S, Li L, Shichinohe T. Pigment Epithelium-Derived Factor Gene Therapy Inhibits Human Pancreatic Cancer in Mice. Clin Cancer Res 2005, 11(24):8737. 10.1158/1078-0432.CCR-05-1323, 16361561.
15. Streck CJ, Zhang Y, Zhou J, Ng C, Nathwani AC, Davidoff AM. Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth. J Pediatr Surg 2005, 40(1):236-243. 10.1016/j.jpedsurg.2004.09.049, 15868591.
16. Yang H, Grossniklaus HE. Constitutive Overexpression of Pigment Epithelium-Derived Factor Inhibition of Ocular Melanoma Growth and Metastasis. Invest Ophthalmol Vis Sci 2010, 51(1):28. 10.1167/iovs.09-4138, 2819011,2819011, 19661223.
17. Yang LP, Cheng P, Peng XC, Shi HS, He WH, Cui FY, Luo ST, Wei YQ, Yang L. Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma. J Exp Clin Cancer Res 2009, 28:75. 10.1186/1756-9966-28-75, 2700809, 19500366.
18. Cavazzana-Calvo M, Hacein-Bey S, Basile GS, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288(5466):669. 10.1126/science.288.5466.669, 10784449.
19. Blau H, Khavari P. Gene therapy: Progress, problems, prospects. Nat Med 1997, 3(6):612-613. 10.1038/nm0697-612, 9176485.
20. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002, 9(24):1647. 10.1038/sj.gt.3301923, 12457277.
21. St George J. Gene therapy progress and prospects: adenoviral vectors. Gene Ther 2003, 10(14):1135-1141. 10.1038/sj.gt.3302071, 12833122.
22. Flotte T. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2004, 11(10):805-810. 10.1038/sj.gt.3302233, 15042119.
23. Sinn P, Sauter S, McCray P. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther 2005, 12(14):1089-1098. 10.1038/sj.gt.3302570, 16003340.
24. Ponnazhagan S, Curiel DT, Shaw DR, Alvarez RD, Siegal GP. Adeno-associated virus for cancer gene therapy. Cancer Res 2001, 61(17):6313.
25. Li C, Bowles DE, Van Dyke T, Samulski RJ. Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther 2005, 12(12):913-925. 10.1038/sj.cgt.7700876, 1361306, 15962012.
26. Ponnazhagan S, Mahendra G, Kumar S, Shaw DR, Stockard CR, Grizzle WE, Meleth S. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 2004, 64(5):1781-1787. 10.1158/0008-5472.CAN-03-1786, 14996740.
27. Subramanian IV, Bui Nguyen TM, Truskinovsky AM, Tolar J, Blazar BR, Ramakrishnan S. Adeno-Associated Virus-Mediated Delivery of a Mutant Endostatin in Combination with Carboplatin Treatment Inhibits Orthotopic Growth of Ovarian Cancer and Improves Long-term Survival. Cancer Res 2006, 66(8):4319. 10.1158/0008-5472.CAN-05-3297, 16618757.
28. Schmidt M, Voutetakis A, Afione S, Zheng C, Mandikian D, Chiorini JA. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid-and heparan sulfate proteoglycan-independent transduction activity. J Virol 2008, 82(3):1399. 10.1128/JVI.02012-07, 2224443, 18045941.
29. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004, 78(12):6381. 10.1128/JVI.78.12.6381-6388.2004, 416542, 15163731.
30. Mori S, Wang L, Takeuchi T, Kanda T. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 2004, 330(2):375-383. 10.1016/j.virol.2004.10.012, 15567432.
31. Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003, 14(11):1079-1088. 10.1089/104303403322124792, 12885347.
32. McCarty D, DiRosario J, Gulaid K, Muenzer J, Fu H. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther 2009, 16(11):1340-1352. 10.1038/gt.2009.85, 19587708.
33. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973, 52(11):2745. 10.1172/JCI107470, 302542, 4355998.
34. Wu X, Dong X, Wu Z, Cao H, Niu D, Qu J, Wang H, Hou Y. A novel method for purification of recombinant adenoassociated virus vectors on a large scale. Chin Sci Bull 2001, 46(6):485-488.
35. Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, Liu Y, Zhao C, Deng S, Yang Y. SKLB1002, A Novel Potent Inhibitor of Vascular Endothelial Growth Factor Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth in Vivo. Clin Canc Res 2011, 17(13):4439.
36. Liu J, Wei Y, Yang L, Zhao X, Tian L, Hou J, Niu T, Liu F, Jiang Y, Hu B. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003, 102(5):1815. 10.1182/blood-2002-12-3772, 12750177.
37. Ben-Sasson SA, Sherman Y, Gavrieli Y. Identification of dying cells-in situ staining. Methods Cell Biol 1995, 46:29-39.
38. Shaheen R, Ahmad S, Liu W, Reinmuth N, Jung Y, Tseng W, Drazan K, Bucana C, Hicklin D, Ellis L. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001, 85(4):584. 10.1054/bjoc.2001.1936, 2364099, 11506500.
39. Endo T, Toda M, Watanabe M, Iizuka Y, Kubota T, Kitajima M, Kawakami Y. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther 2002, 9(2):142-148. 10.1038/sj.cgt.7700407, 11857031.
40. Ning T, Yan X, Lu ZJ, Wang GP, Zhang NG, Yang JL, Jiang SS, Wu Y, Yang L, Guan YS. Gene Therapy with the Angiogenesis Inhibitor Endostatin in an Orthotopic Lung Cancer Murine Model. Hum Gene Ther 2009, 20(2):103-111. 10.1089/hum.2008.098, 18939902.
41. Samulski RJ, Berns KI, Tan M, Muzyczka N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci 1982, 79(6):2077. 10.1073/pnas.79.6.2077, 346126, 6281795.
42. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006, 14(3):316-327. 10.1016/j.ymthe.2006.05.009, 16824801.
43. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011, 12(5):341-355. 10.1038/nrg2988, 21499295.
44. Georg-Fries B, Biederlack S, Wolf J, Zur Hausen H. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology 1984, 134(1):64-71. 10.1016/0042-6822(84)90272-1, 6200995.
45. Erles K, Sebökovà P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999, 59(3):406-411. 10.1002/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N, 10502275.